SG11201609853VA - Intermittent dosing of mdm2 inhibitor - Google Patents
Intermittent dosing of mdm2 inhibitorInfo
- Publication number
- SG11201609853VA SG11201609853VA SG11201609853VA SG11201609853VA SG11201609853VA SG 11201609853V A SG11201609853V A SG 11201609853VA SG 11201609853V A SG11201609853V A SG 11201609853VA SG 11201609853V A SG11201609853V A SG 11201609853VA SG 11201609853V A SG11201609853V A SG 11201609853VA
- Authority
- SG
- Singapore
- Prior art keywords
- mdm2 inhibitor
- intermittent dosing
- dosing
- intermittent
- mdm2
- Prior art date
Links
- 229940083338 MDM2 inhibitor Drugs 0.000 title 1
- 239000012819 MDM2-Inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462017406P | 2014-06-26 | 2014-06-26 | |
PCT/IB2015/054792 WO2015198266A1 (en) | 2014-06-26 | 2015-06-25 | Intermittent dosing of mdm2 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201609853VA true SG11201609853VA (en) | 2017-01-27 |
Family
ID=53510950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201609853VA SG11201609853VA (en) | 2014-06-26 | 2015-06-25 | Intermittent dosing of mdm2 inhibitor |
Country Status (18)
Country | Link |
---|---|
US (6) | US20170196866A1 (en) |
EP (1) | EP3160463B1 (en) |
JP (1) | JP6728072B2 (en) |
KR (3) | KR20220151027A (en) |
CN (2) | CN106456635A (en) |
AU (1) | AU2015278765B2 (en) |
BR (1) | BR112016029750A2 (en) |
CA (1) | CA2953079C (en) |
CL (1) | CL2016003295A1 (en) |
ES (1) | ES2856210T3 (en) |
IL (1) | IL249138B (en) |
MX (1) | MX2016017075A (en) |
PH (1) | PH12016502556A1 (en) |
RU (1) | RU2695228C2 (en) |
SG (1) | SG11201609853VA (en) |
TN (1) | TN2016000522A1 (en) |
TW (1) | TW201613576A (en) |
WO (1) | WO2015198266A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2610531T3 (en) | 2007-03-28 | 2017-04-28 | President And Fellows Of Harvard College | Sewn polypeptides |
ES2711526T3 (en) | 2010-08-13 | 2019-05-06 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
RU2639523C2 (en) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Peptidomimetic macrocycles and their application |
AU2013337388B2 (en) | 2012-11-01 | 2018-08-02 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
SG11201702175YA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
KR20170058424A (en) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | Peptidomimetic macrocycles and uses thereof |
EP3294318A4 (en) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
CA3043004A1 (en) * | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
MX2019011620A (en) * | 2017-03-31 | 2019-12-05 | Novartis Ag | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors. |
WO2019174576A1 (en) * | 2018-03-12 | 2019-09-19 | 罗欣药业(上海)有限公司 | Imidaxopyrolone compound and application thereof |
AU2019240200B2 (en) | 2018-03-20 | 2022-07-21 | Novartis Ag | Pharmaceutical combinations |
TWI741286B (en) * | 2018-04-30 | 2021-10-01 | 美商卡托斯醫療公司 | Methods of treating cancer |
JP2022514280A (en) * | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | Extended low-dose regimen for MDM2 inhibitors |
TW202123941A (en) | 2019-09-16 | 2021-07-01 | 瑞士商諾華公司 | Use of an mdm2 inhibitor for the treatment of myelofibrosis |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
US20030139373A1 (en) | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
CN101160314B (en) | 2005-02-22 | 2012-05-23 | 密执安州立大学董事会 | Small molecule inhibitors of mdm2 and the uses thereof |
US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
CN102770182B (en) * | 2009-12-22 | 2014-10-29 | 诺华股份有限公司 | Substituted isoquinolinones and quinazolinones |
EP2361667B1 (en) | 2010-02-25 | 2015-04-01 | Alstom Technology Ltd | A wet scrubber and a method of cleaning a process gas |
NZ611866A (en) * | 2010-11-12 | 2015-04-24 | Univ Michigan | Spiro-oxindole mdm2 antagonists |
EP2651976A1 (en) * | 2010-12-16 | 2013-10-23 | Roche Glycart AG | Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor |
US9579329B2 (en) | 2011-08-11 | 2017-02-28 | Estetra S.P.R.L. | Use of estetrol as emergency contraceptive |
EP2793890B1 (en) | 2011-12-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
UY34591A (en) | 2012-01-26 | 2013-09-02 | Novartis Ag | IMIDAZOPIRROLIDINONA COMPOUNDS |
US20130245089A1 (en) | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
CN104520714A (en) * | 2012-07-31 | 2015-04-15 | 诺华股份有限公司 | Markers associated with sensitivity to inhibitors of human double minute 2 (MDM2) |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
PE20160591A1 (en) | 2013-12-05 | 2016-06-11 | Hoffmann La Roche | NEW COMBINATION TREATMENT FOR ACUTE MYELOID LEUKEMIA (AML) |
RU2684106C2 (en) | 2013-12-23 | 2019-04-04 | Новартис Аг | Pharmaceutical combinations |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
CN108025006A (en) | 2015-02-06 | 2018-05-11 | 尤尼蒂生物技术公司 | Compound and the purposes in aging-related disorders are treated |
CA2982435C (en) | 2015-04-13 | 2020-05-26 | Daiichi Sankyo Company, Limited | Treatment method by combined use of mdm2 inhibitor and btk inhibitor |
TWI750129B (en) | 2015-08-03 | 2021-12-21 | 瑞士商諾華公司 | Gdf-15 as a haematological toxicity biomarker |
EP3340989B1 (en) | 2015-08-28 | 2023-08-16 | Novartis AG | Mdm2 inhibitors and combinations thereof |
CA3043004A1 (en) | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
WO2018096440A1 (en) | 2016-11-22 | 2018-05-31 | Novartis Ag | Chemical process for preparing imidazopyrrolidinone derivatives and intermediates thereof |
WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
MX2019011620A (en) | 2017-03-31 | 2019-12-05 | Novartis Ag | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors. |
CN111163781B (en) | 2017-10-12 | 2023-05-16 | 诺华股份有限公司 | Combination of MDM2 inhibitors and ERK inhibitors for the treatment of cancer |
AU2019240200B2 (en) | 2018-03-20 | 2022-07-21 | Novartis Ag | Pharmaceutical combinations |
WO2020092221A1 (en) | 2018-10-30 | 2020-05-07 | Dana-Farber Cancer Institute, Inc. | Method of treatment of p53 wt tumors |
JP2022514280A (en) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | Extended low-dose regimen for MDM2 inhibitors |
KR20210149039A (en) | 2019-04-04 | 2021-12-08 | 노파르티스 아게 | Syremadeline Succinate |
-
2015
- 2015-06-24 TW TW104120384A patent/TW201613576A/en unknown
- 2015-06-25 BR BR112016029750A patent/BR112016029750A2/en not_active Application Discontinuation
- 2015-06-25 TN TN2016000522A patent/TN2016000522A1/en unknown
- 2015-06-25 AU AU2015278765A patent/AU2015278765B2/en active Active
- 2015-06-25 KR KR1020227037821A patent/KR20220151027A/en not_active IP Right Cessation
- 2015-06-25 JP JP2016574274A patent/JP6728072B2/en active Active
- 2015-06-25 CN CN201580034558.4A patent/CN106456635A/en not_active Withdrawn
- 2015-06-25 EP EP15733926.8A patent/EP3160463B1/en active Active
- 2015-06-25 SG SG11201609853VA patent/SG11201609853VA/en unknown
- 2015-06-25 WO PCT/IB2015/054792 patent/WO2015198266A1/en active Application Filing
- 2015-06-25 CN CN202211129314.2A patent/CN115569197A/en active Pending
- 2015-06-25 MX MX2016017075A patent/MX2016017075A/en unknown
- 2015-06-25 CA CA2953079A patent/CA2953079C/en active Active
- 2015-06-25 RU RU2017102319A patent/RU2695228C2/en active
- 2015-06-25 US US15/321,042 patent/US20170196866A1/en not_active Abandoned
- 2015-06-25 KR KR1020167035797A patent/KR102462177B1/en active IP Right Grant
- 2015-06-25 ES ES15733926T patent/ES2856210T3/en active Active
- 2015-06-25 KR KR1020247021711A patent/KR20240110659A/en not_active Application Discontinuation
-
2016
- 2016-11-22 IL IL249138A patent/IL249138B/en active IP Right Grant
- 2016-12-20 PH PH12016502556A patent/PH12016502556A1/en unknown
- 2016-12-22 CL CL2016003295A patent/CL2016003295A1/en unknown
-
2017
- 2017-12-21 US US15/849,770 patent/US20180110779A1/en not_active Abandoned
-
2018
- 2018-12-17 US US16/221,650 patent/US20190209561A1/en not_active Abandoned
-
2020
- 2020-06-11 US US16/898,886 patent/US11419870B2/en active Active
-
2022
- 2022-07-25 US US17/814,599 patent/US20230092181A1/en not_active Abandoned
-
2024
- 2024-04-11 US US18/632,528 patent/US20240261284A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288519B1 (en) | Inhibitors of ret | |
IL287113A (en) | Smyd inhibitors | |
IL249138B (en) | Intermittent dosing of mdm2 inhibitor | |
IL251584A0 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
IL246902A0 (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
ZA201604272B (en) | Inhibitors of glutaminase | |
IL248895A0 (en) | Phosphatidylinositol -kinase inhibitors | |
EP3183255C0 (en) | Spiropyrrolidines as mdm2 inhibitors | |
GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
GB201420627D0 (en) | Application of adhesives | |
HUP1400294A2 (en) | Novel application of clopidogrel | |
GB201418154D0 (en) | Inhibitors | |
GB201418230D0 (en) | Construction of surfaces | |
GB201417343D0 (en) | Prodrugs of bortezomib | |
GB201414132D0 (en) | Prodrugs of bortezomib | |
GB201413139D0 (en) | Assessment of structures | |
GB201413138D0 (en) | Assessment of structures |